Riluzole

Generic Name: Riluzole

Brand Names: Exservan, Rilutek, Tiglutik, Riluzole Zentiva

Drug Type: Small Molecule

Chemical Formula: C_₈H_₅F_₃N_₂OS

CAS Number: 1744-22-5

Unique Ingredient Identifier: 7LJ087RS6F

Background: A glutamate antagonist (receptors, glutamate) used as an anticonvulsant (anticonvulsants) and to prolong the survival of patients with amyotrophic lateral sclerosis. Riluzole is marketed as Rilutek by Sanofi.

Indication: For the treatment of amyotrophic lateral sclerosis (ALS, Lou Gehrig's Disease)

Associated Conditions: Amyotrophic Lateral Sclerosis (ALS)

Clinical Trials

Pharmacokinetics of Y-4 Tablets With Pregabalin Capsules and Riluzole Tablets in Chinese Healthy Subject

Phase 1

Recruiting

Conditions: Healthy Male and Female Subjects

Interventions: Drug: Y-4 tablet
Drug: Pregabalin capsule
Drug: Riluzole tablet

First Posted Date: 2025-04-20

Last Posted Date: 2025-04-20

Lead Sponsor: Beijing Tiantan Hospital

Target Recruit Count: 10

Registration Number: NCT06935721

Locations: 🇨🇳
Beijing Tiantan Hospital, Capital Medical University Beijing, Beijing, Beijing, China

Evaluate the Safety of Neuronata-R® Inj. Suspended With HypoTHermosol® FRS (HTS-FRS) in Patients With ALS

Phase 1

Completed

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Biological: Lenzumestrocel
Drug: Riluzole

First Posted Date: 2024-11-06

Last Posted Date: 2024-11-06

Lead Sponsor: Corestemchemon, Inc.

Target Recruit Count: 8

Registration Number: NCT06676423

Locations: 🇰🇷
Hanyang university hospital, Seoul, Korea, Republic of

Repurposing Riluzole for Cancer-Related Cognitive Impairment: a Pilot Trial

Phase 2

Recruiting

Conditions: Breast Cancer

Interventions: Drug: Riluzole
Drug: Placebo

First Posted Date: 2024-08-30

Last Posted Date: 2025-03-27

Lead Sponsor: University of California, Irvine

Target Recruit Count: 34

Registration Number: NCT06580002

Locations: 🇺🇸
Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, California, United States

The Role of Glutamatergic Function in the Pathophysiology of Treatment-resistant Schizophrenia

Early Phase 1

Recruiting

Conditions: Treatment-resistant Schizophrenia
Treatment-responsive Schizophrenia
Healthy Controls

Interventions: Drug: Riluzole

First Posted Date: 2024-02-21

Last Posted Date: 2024-03-05

Lead Sponsor: King's College London

Target Recruit Count: 288

Registration Number: NCT06270108

Locations: 🇬🇧
Institute of Psychiatry, Psychology and Neuroscience, London, United Kingdom

Treatment Combining Riluzole and IFB-088 in Bulbar Amyotrophic Lateral Sclerosis (TRIALS Protocol)

Phase 2

Completed

Conditions: Amyotrophic Lateral Sclerosis
ALS

Interventions: Drug: IFB-088 50mg/day
Drug: Placebo
Drug: Riluzole 100mg/day

First Posted Date: 2022-08-19

Last Posted Date: 2025-04-06

Lead Sponsor: InFlectis BioScience

Target Recruit Count: 51

Registration Number: NCT05508074

Locations: 🇫🇷
Hôpital Neurologique Pierre Wertheimer, Bron, France
🇫🇷
APHM Hôpital La Timone Adultes SCE Maladies Neuromusculaires / SLA, Marseille Cedex 05, France
🇫🇷
CHU de Nantes - Hôpital Laennec, Nantes, France

and more 6 locations

RiLuzole to Reduce Atrial FIb Study Using Holter Monitoring

Phase 2

Recruiting

Conditions: Atrial Fibrillation Paroxysmal

Interventions: Drug: Riluzole 50 MG

First Posted Date: 2022-03-23

Last Posted Date: 2023-11-24

Lead Sponsor: University of Utah

Target Recruit Count: 78

Registration Number: NCT05292209

Locations: 🇺🇸
University of Utah, Salt Lake City, Utah, United States

The Treatment of Amyotrophic Lateral Sclerosis With Huollingshengji Granules

Phase 2

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: Riluzole tablet
Drug: Huolingshengji Granules

First Posted Date: 2021-07-06

Last Posted Date: 2021-07-08

Lead Sponsor: Peking University Third Hospital

Target Recruit Count: 144

Registration Number: NCT04950933

Locations: 🇨🇳
Peking University Third Hospital, Beijin, China

Riluzole in Combination With mFOLFOX6 and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

Phase 1

Completed

Conditions: Stage IVA Colorectal Cancer AJCC v8
Stage IVB Colorectal Cancer AJCC v8
Stage IVC Colorectal Cancer AJCC v8
Metastatic Colorectal Carcinoma
Stage IV Colorectal Cancer AJCC v8

Interventions: Biological: Bevacizumab
Drug: Fluorouracil
Drug: Leucovorin Calcium
Drug: Oxaliplatin
Drug: Riluzole

First Posted Date: 2021-02-21

Last Posted Date: 2025-03-28

Lead Sponsor: Ning Jin

Target Recruit Count: 13

Registration Number: NCT04761614

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Evaluation the Efficacy and Safety of Mutiple Lenzumestrocel (Neuronata-R® Inj.) Treatment in Patients with ALS

Phase 3

Active, not recruiting

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Biological: Lenzumestrocel
Drug: Riluzole
Drug: Placebo Comparator

First Posted Date: 2021-02-09

Last Posted Date: 2025-01-10

Lead Sponsor: Corestemchemon, Inc.

Target Recruit Count: 115

Registration Number: NCT04745299

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
🇰🇷
Pusan National University Yangsan Hospital, Yangsan, Kyungsangnam-do, Korea, Republic of

and more 2 locations

Riluzole Effects on Hippocampus Biomarkers

Early Phase 1

Completed

Conditions: Posttraumatic Stress Disorder

Interventions: Drug: Riluzole

First Posted Date: 2020-11-16

Last Posted Date: 2020-11-16

Lead Sponsor: Mclean Hospital

Target Recruit Count: 20

Registration Number: NCT04630444

Locations: 🇺🇸
McLean Hospital, Belmont, Massachusetts, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy